SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the company is a deep-value opportunity or a struggling incumbent in the face of competitive pressure from agentic AI. While community members are polarized over recent price declines, the core discussion focuses on the firm's cash-rich, debt-free balance sheet and its potential for a turnaround through its ongoing strategic pivot toward enterprise AI orchestration.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is capturing significant investor attention following the expansion of its multi-year compute agreement with Meta, now valued at over $35 billion, and a new strategic partnership to power Anthropic's Claude models. While the community is actively debating the stock's potential for a major breakout and the impact of its aggressive infrastructure debt financing, sentiment remains divided between those betting on the company's critical role in the AI compute race and skeptics wary of its long-term leverage and potential for shareholder dilution.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing significant downward pressure and all-time low sentiment despite an investor day focused on long-term growth through a new midsize vehicle platform, robotaxi ambitions, and potential partnerships. Community members are sharply divided, with bulls pointing to Saudi financial backing and future product cycles as a deep-value opportunity, while bears remain fixated on persistent cash burn, recurring vehicle recalls, and the stock's ongoing decline.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense debate as investors weigh strong government contract momentum against skepticism from figures like Michael Burry, whose recent commentary has fueled volatility. Sentiment is further polarized by a high-profile presidential endorsement, which has sparked aggressive discussion about potential market manipulation versus legitimate valuation corrections in the AI software sector.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing high volatility as investors weigh strong quarterly revenue growth and AI product momentum against broader sector-wide concerns about AI-driven disruption. While the community is debating whether the current sell-off reflects a structural shift or a temporary repricing of software multiples, many are watching key technical support levels to see if the stock can stabilize after its recent breakdown.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a sharp sell-off as investors grapple with sector-wide pressure and growing concerns that AI-driven disruption from companies like Anthropic could commoditize traditional enterprise software. While the stock has hit fresh multi-year lows, the community remains deeply divided, with some calling for capitulation and others identifying the pullback as a generational buying opportunity tied to the company's long-term enterprise infrastructure role.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors react to a recent analyst upgrade and the company's decision to walk away from a potential Warner Bros. Discovery acquisition, with the community closely tracking its momentum toward the key $100 resistance level. Bullish sentiment is fueled by expectations of strong organic growth, while traders remain highly focused on upcoming earnings and potential technical breakouts.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense investor activity as the community reacts to its recent foundry integration news and growing momentum in the photonics sector. Traders are closely tracking the stock's ability to maintain its newfound price levels while debating whether this is a sustainable breakout driven by institutional accumulation or a speculative move vulnerable to broader market volatility.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing intense market interest and a sharp price surge driven by unconfirmed headlines regarding a potential $12 billion acquisition bid by Sun Pharma. While the community is actively debating the credibility of the reports and the impact of the company's significant debt load, the stock remains a focal point for M&A speculators and those tracking a potential breakout.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is currently trending as a community-driven memecoin that leverages long-standing internet lore to position itself as a satirical counterpoint to Bitcoin. Participants are actively discussing its potential for significant market movement, focusing on the cultural irony of its 'store of butts' branding and its origins within historical crypto forums.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics (NASDAQ:TVTX)  Shares Down 7.8%   - Should You Sell?

Travere Therapeutics (NASDAQ:TVTX) Shares Down 7.8% - Here's What Happened...

<ul class="summary-bullets"><li>The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.</li><li>Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.</li><li>If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder.</li></ul>Shares of Travere Therapeutics (TVTX) and Ligand Pharmaceuticals (LGND) are drawing increased investor attention ahead of a key U.S. Food and Drug Administration decision on Filspari, a treatment for a rare kidney disease, expected on April 13.Ligand has a licensing agreement with Travere for Sparsentan, sold under the Filspari brand, under which Ligand will receive milestone payments and a 9% royalty on future global net sales of the drug.At the time of writing, <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> and <a href="https://stocktwits.com/symbol/LGND">LGND</a> shares were little changed in pre-market trading on Friday.<h2 class="st-heading-2">FDA Did Not Seek Additional Information On Safety And Manufacturing</h2>In January, Travere Therapeutics announced that the FDA extended the review of its supplemental New Drug Application (sNDA) for Filspari in focal segmental glomerulosclerosis (FSGS), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The FDA did not request any additional information related to the drug’s safety or manufacturing.A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder that can lead to progressive loss of kidney function and eventual kidney failure. Filspari is an oral, non-immunosuppressive therapy.<h2 class="st-heading-2">Citi Expects FDA Approval</h2>Last month, Citi maintained Travere Therapeutics’ ‘Buy’ rating and $48 price target. The firm expects the FDA to approve Filspari and added that the current share price does not fully reflect the company’s opportunity in FSGS.Travere’s Phase 3 study met its interim goal for proteinuria reduction but did not meet the primary kidney function endpoint. However, longer-term results showed the drug improved proteinuria, remission rates, and reduced progression to kidney failure, while remaining well-tolerated. Proteinuria is the high concentration of protein, usually albumin, in urine.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits was ‘bullish’ for TVTX and ‘neutral’ for LGND.One user expects TVTX stock to decline if there is no update before Friday’s close.<stembedurl>https://stocktwits.com/Smellmahass/message/649764886</stembedurl>However, another user expected a pre-FDA run-up to $32 - $35.<stembedurl>https://stocktwits.com/Buckeyeboy722/message/649091978</stembedurl>Year-to-date, TVTX shares have declined 20% while LGND stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake 

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari

Equity

Travere Therapeutics (NASDAQ:TVTX) Director Sells $330,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy Baynes sold 10,000 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the director owned...

Aberdeen Group plc Trims Holdings in Travere Therapeutics, Inc. $TVTX

Aberdeen Group plc trimmed its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 46.4% in the 4th quarter, according to the company in its most recent disclosure with the...

Travere Therapeutics (NASDAQ:TVTX) Shares Up 7.7% - Still a Buy?

Travere Therapeutics (NASDAQ:TVTX) Trading 7.7% Higher - Should You Buy...

Palisades Investment Partners LLC Invests $5.26 Million in Travere Therapeutics, Inc. $TVTX

Palisades Investment Partners LLC purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities...

Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold...

Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 60,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price...

Hennion & Walsh Asset Management Inc. Increases Position in Travere Therapeutics, Inc. $TVTX

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 169.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,229 shares of the company's stock aft...

Tudor Investment Corp ET AL Cuts Stake in Travere Therapeutics, Inc. $TVTX

Tudor Investment Corp ET AL cut its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 52.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 95,747 shares of the company's stock after s...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Current Price	$28.96
Prev Close	$31.44
Open	$31.25
Dividend Yield	0.00%
50-Day Moving Average	$29.37
Beta	1.51
Avg. Volume	1.25M
PE Ratio	-52.14

52-Week High	$42.13
52-Week Low	$13.14
Market Capitalization	$2.9B
EPS (Annual)	-$0.5634
Price to Book	24.89
Revenue Per Employee	$987,380.28

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TVTX News

TVTXTravere Therapeutics Inc